LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results ( LEADER ) trial: preliminary observations
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Aims: To report preliminary data on baseline serum calcitonin concentrations and associated clinical characteristics in a global population with type 2 diabetes before liraglutide or placebo randomization. Methods: The ongoing LEADER trial has enrolled 9340 people with type 2 diabetes and at high risk of cardiovascular disease at 410 centres worldwide. People with baseline serum calcitonin ≤50 ng/l were randomized to liraglutide once daily or placebo and will be followed for up to 5 years. Serum calcitonin was measured at baseline and will be measured annually thereafter. An independent committee of thyroid experts will oversee calcitonin monitoring throughout the trial and will review all calcitonin concentrations ≥20 ng/l. Results: The mean age of participants was 64.3 ± 7.2 years, 64.3% were men, and mean the body mass index was 32.5 ± 6.3 kg/m 2 . The median (interquartile range) baseline serum calcitonin values were 3.9 (1.0 to >7.6) ng/l in men and 1.0 (1.0 to >1) ng/l in women. Serum calcitonin was >10 ng/l in 14.6% of men and in 0.96% of women. In sex‐specific multivariable linear analysis of covariance models, a reduced glomerular filtration rate ( GFR ) was associated with higher serum calcitonin concentrations that were statistically significant. A 20 ml/min/1.73 m 2 decrease in estimated GFR ( eGFR ) was associated with a 14% increase in serum calcitonin in women and an 11% increase in men. Conclusions: In the LEADER population, the prevalence of elevated serum calcitonin concentrations at baseline was high, and there was an inverse association between eGFR and serum calcitonin concentrations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · cited 1×
“Liraglutide is a glucagon-like peptide 1 (GLP-1) analogue approved for use in adults with type 2 diabetes mellitus [1,2].”
BackgroundSelf-citationGarber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057 · cited 1×
“Liraglutide is a glucagon-like peptide 1 (GLP-1) analogue approved for use in adults with type 2 diabetes mellitus [1,2].”
BackgroundBjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 2×
“C-cell pathology was absent in liraglutide-treated GLP-1 receptor knockout animals [3,4],”
BackgroundSelf-citationHegedüs, L., Moses, A. C., Zdravkovic, M., Le Thi, T., & Daniels, G. H. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2318 · Cited by 194 · cited 3×
“In combined data from nine studies of ≥20 weeks’ duration, including>5000 subjects with either type 2 diabetes or obesity without diabetes, there was no significant difference in the proportion of subjects with calcitonin concentrations>20 ng/l in the liraglutide versus the placebo groups [5].”
BackgroundInfluentialSelf-citationThyroid nodule guidelines: agreement, disagreement and need for future research
Paschke, R., Hegedüs, L., Alexander, E., Valcavi, R., Papini, E., & Gharib, H. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.1 · Cited by 184 · cited 1×
“For these reasons the role of serum calcitonin measurements in screening for MTC in the thyroid nodule population is controversial, and uncertainty is even greater concerning the specificity of indeterminate calcitonin concentrations in people without known thyroid abnormalities and with other medical conditions such…”
BackgroundSelf-citationMadsen, L. W., Knauf, J. A., Gotfredsen, C., Pilling, A., Sjögren, I., Andersen, S., Andersen, L., Sietske de Boer, A., Manova, K., Barlas, A., et al. (2012) · Endocrinology · doi:10.1210/en.2011-1864 · Cited by 161 · cited 1×
“C-cell pathology was absent in liraglutide-treated GLP-1 receptor knockout animals [3,4],”
Background
Cited by
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Nauck, M., Rizzo, M., Johnson, A., Bosch-Traberg, H., Madsen, J., & Cariou, B. (2016) · Diabetes Care · doi:10.2337/dc15-2479 · Cited by 143
Self-citationUser’s guide to mechanism of action and clinical use of GLP-1 receptor agonists
Shaefer, C. F., Kushner, P., & Aguilar, R. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1090295 · Cited by 128
Hegedüs, L., Sherman, S. I., Tuttle, R. M., von Scholten, B. J., Rasmussen, S., Karsbøl, J. D., Daniels, G. H., & for the LEADER Publication Committee on behalf of the LEADER Trial Investigators (2018) · Diabetes Care · doi:10.2337/dc17-1956 · Cited by 67
Self-citation
Metadata
- Authors
- Daniels, G. H., Hegedüs, L., Marso, S. P., Nauck, M. A., Zinman, B., Bergenstal, R. M., Mann, J. F. E., Derving Karsbøl, J., Moses, A. C., Buse, J. B., Tuttle, R. M., & on behalf of the LEADER trial investigators
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2015-02-23
- Volume
- 17
- Issue
- 5
- Pages
- 477-486
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2114506972
- Cited by
- 42
- References
- 6
- FWCI
- 2.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results ( LEADER ) trial: preliminary observations. https://app.cochat.ai/papers/10.1111/dom.12444
- The paper
- Daniels, G. H., Hegedüs, L., Marso, S. P., Nauck, M. A., Zinman, B., Bergenstal, R. M., Mann, J. F. E., Derving Karsbøl, J., Moses, A. C., Buse, J. B., Tuttle, R. M., & on behalf of the LEADER trial investigators. (2015). LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results ( LEADER ) trial: preliminary observations. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12444
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.